M&A Deal Summary

Inotiv Acquires HistoTox Labs

On April 13, 2021, Inotiv acquired life science company HistoTox Labs for 22M USD

Acquisition Highlights
  • This is Inotiv’s 3rd transaction in the Life Science sector.
  • This is Inotiv’s 2nd largest (disclosed) transaction.
  • This is Inotiv’s 3rd transaction in the United States.
  • This is Inotiv’s 1st transaction in Colorado.

M&A Deal Summary
Date 2021-04-13
Target HistoTox Labs
Sector Life Science
Buyer(s) Inotiv
Deal Type Add-on Acquisition
Deal Value 22M USD

Target

HistoTox Labs

Boulder, Colorado, United States
website
HistoTox Labs is a full-service histopathology contract research organization (CRO) offering medically relevant non-clinical and clinical services to the pharmaceutical, biotech, and academic communities.

Search 192,349 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Inotiv

West Lafayette, Indiana, United States

website

Category Company
Founded 1974
Sector Life Science
Employees2,099
Revenue 548M USD (2022)
DESCRIPTION

Inotiv is a pharmaceutical development company providing contract research services and niche instrumentation, serving both the life sciences industries, primarily in drug research and development. Inotiv was founded in 1974 and is based in West Lafayette, Indiana.

DEAL STATS #
Overall 3 of 9
Sector (Life Science) 3 of 8
Type (Add-on Acquisition) 2 of 7
State (Colorado) 1 of 3
Country (United States) 3 of 9
Year (2021) 1 of 3
Size (of disclosed) 2 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-05-01 The Smithers Group - Avanza Bioanalytical Services Business

Gaithersburg, Maryland, United States

The Smithers Group - Avanza Bioanalytical Services Business is a boutique contract research organization (CRO) specializing in general toxicology, vaccine safety and developmental and reproductive toxicology (DART).

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-04-16 Bolder BioPATH

Boulder, Colorado, United States

Bolder BioPATH is a contract pharmacology and pathology company specializing in vivo models of rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, diseases of the central nervous system, and other autoimmune, inflammation, and pain models. Bolder BioPATH was founded in 2003 and is based in Boulder, Colorado.

Buy $20M
Mergr

Product

Company

Legal